April 29, 2015 / 11:44 AM / 3 years ago

BUZZ-Oncolytics Biotech Inc: Lead cancer drug gets orphan drug status

** Drug developer’s U.S.-listed shares up 6.21 pct at $0.75 premarket

** Company’s lead pancreatic cancer drug, Reolysin, gets orphan drug status from European health regulator

** Orphan status, granted to drugs developed to treat rare diseases, gives developer several incentives including seven-year U.S. marketing exclusivity

** Up to Tuesday’s close, stock gained 32 pct this year

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below